183 related articles for article (PubMed ID: 38110280)
21. Outcome and surgical strategy in critical sites in cases of psuedomyxoma peritonei.
Mahmoud AM; Hussein MM; Moneer MM
J Egypt Natl Canc Inst; 2016 Dec; 28(4):249-255. PubMed ID: 27658904
[TBL] [Abstract][Full Text] [Related]
22. Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: A single-center retrospective analysis of 125 patients.
Ji ZH; Yu Y; Liu G; Zhang YB; An SL; Li B; Li XB; Yan GJ; Li Y
Eur J Surg Oncol; 2021 Jun; 47(6):1411-1419. PubMed ID: 33293213
[TBL] [Abstract][Full Text] [Related]
23. Development and Validation of Nomograms to Predict Survival in Patients Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei of Appendiceal Origin.
Chandrakumaran K; Carr NJ; Mohamed F; Cecil TD; Moran BJ
JAMA Surg; 2023 May; 158(5):522-530. PubMed ID: 36920381
[TBL] [Abstract][Full Text] [Related]
24. Hyperthermic intraperitoneal chemotherapy with oxaliplatin as treatment for peritoneal carcinomatosis arising from the appendix and pseudomyxoma peritonei: a survival analysis.
Marcotte E; Dubé P; Drolet P; Mitchell A; Frenette S; Leblanc G; Leclerc YE; Sideris L
World J Surg Oncol; 2014 Nov; 12():332. PubMed ID: 25380618
[TBL] [Abstract][Full Text] [Related]
25. Health related quality of life is excellent and sustained at two decades after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in survivors of pseudomyxoma peritonei of appendiceal origin.
Kung V; Delisle M; Alves S; Mohamed F; Cecil T; Moran B
Eur J Surg Oncol; 2023 Nov; 49(11):107045. PubMed ID: 37677915
[TBL] [Abstract][Full Text] [Related]
26. High-grade postoperative complications affect survival outcomes of patients with colorectal Cancer peritoneal metastases treated with Cytoreductive surgery and Hyperthermic Intraperitoneal chemotherapy.
Zhou S; Feng Q; Zhang J; Zhou H; Jiang Z; Liu Z; Zheng Z; Chen H; Wang Z; Liang J; Pei W; Liu Q; Zhou Z; Wang X
BMC Cancer; 2021 Jan; 21(1):41. PubMed ID: 33413223
[TBL] [Abstract][Full Text] [Related]
27. Early postoperative intraperitoneal chemotherapy (EPIC) following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in 632 patients with pseudomyxoma peritonei of appendiceal origin: A single institution experience.
Fung X; Li IC; Chandrakumaran K; Cecil T; Dayal S; Tzivanakis A; Moran B; Mohamed F
Eur J Surg Oncol; 2022 Jul; 48(7):1614-1618. PubMed ID: 35168851
[TBL] [Abstract][Full Text] [Related]
28. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei and appendix tumours in elderly patients: Is it justified?
López-López V; Cascales-Campos PA; Gil E; Arevalo J; Gonzalez A; Gil J; Muñoz-Casares FC; Melero JT; Barrios P; Morales R; Ramos I; Ortega G; Camps B; González-Bayón L; Bretcha-Boix P; Farré-Alegre J; González-Moreno S; Parrilla P
Clin Transl Oncol; 2017 Nov; 19(11):1388-1392. PubMed ID: 28812240
[TBL] [Abstract][Full Text] [Related]
29. Appendiceal pseudomyxoma peritonei: predictors of recurrence and iterative surgery.
Kong JC; Flood MP; Guerra GR; Liesegang A; Wong WJ; Mitchell C; Warrier SK; Naidu S; Meade B; Lutton N; Heriot AG
Colorectal Dis; 2021 Sep; 23(9):2368-2375. PubMed ID: 34157209
[TBL] [Abstract][Full Text] [Related]
30. [Prognostic value of clinical and pathological characteristics in 48 women with pseudomyxoma peritonei].
Lu YY; Guo AT; Liu AJ; Shi HY
Zhonghua Fu Chan Ke Za Zhi; 2013 Aug; 48(8):595-601. PubMed ID: 24199925
[TBL] [Abstract][Full Text] [Related]
31. Outcomes from cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal epithelial neoplasms.
Narasimhan V; Pham T; Warrier S; Craig Lynch A; Michael M; Tie J; Ramsay R; Heriot A
ANZ J Surg; 2019 Sep; 89(9):1035-1040. PubMed ID: 30685879
[TBL] [Abstract][Full Text] [Related]
32. Laparoscopic cytoreductive surgery and HIPEC in LAMN with small volume of peritoneal disease: a valuable option of treatment for good patient-related experience measures (PREMs).
Cusumano C; Carrere S; Bouillin A; Nougaret S; Khellaf L; Quénet F; Sgarbura O
Surg Endosc; 2022 Jul; 36(7):4757-4763. PubMed ID: 34845545
[TBL] [Abstract][Full Text] [Related]
33. Twenty-years' experience with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for pseudomyxoma peritonei (PMP).
Papantoni E; Ntatsis K; Kyziridis D; Kalakonas A; Hristakis C; Tentes AA
J BUON; 2021; 26(4):1647-1652. PubMed ID: 34565031
[TBL] [Abstract][Full Text] [Related]
34. Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours.
Lord AC; Shihab O; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
Eur J Surg Oncol; 2015 Mar; 41(3):396-9. PubMed ID: 25216980
[TBL] [Abstract][Full Text] [Related]
35. Preoperative systemic chemotherapy does not benefit for appendiceal pseudomyxoma peritonei.
Ma R; Lu D; Xue S; Fan X; Zhai X; Wang C; Xu H; Pang S
ANZ J Surg; 2023 Jan; 93(1-2):219-226. PubMed ID: 36136728
[TBL] [Abstract][Full Text] [Related]
36. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.
Vaira M; Cioppa T; DE Marco G; Bing C; D'Amico S; D'Alessandro M; Fiorentini G; DE Simone M
In Vivo; 2009; 23(4):639-44. PubMed ID: 19567401
[TBL] [Abstract][Full Text] [Related]
37. Outcomes Following Cytoreduction and HIPEC for Pseudomyxoma Peritonei: 10-Year Experience.
Narasimhan V; Wilson K; Britto M; Warrier S; Lynch AC; Michael M; Tie J; Akhurst T; Mitchell C; Ramsay R; Heriot A
J Gastrointest Surg; 2020 Apr; 24(4):899-906. PubMed ID: 31090036
[TBL] [Abstract][Full Text] [Related]
38. Survival after complete cytoreductive surgery and HIPEC for extensive pseudomyxoma peritonei.
Benhaim L; Faron M; Gelli M; Sourrouille I; Honoré C; Delhorme JB; Elias D; Goere D
Surg Oncol; 2019 Jun; 29():78-83. PubMed ID: 31196498
[TBL] [Abstract][Full Text] [Related]
39. Managing Recurrent Pseudomyxoma Peritonei in 430 Patients After Complete Cytoreduction and HIPEC: A Dilemma for Patients and Surgeons.
Ahmadi N; Kostadinov D; Sakata S; Ball WR; Gandhi J; Carr NJ; Tzivanakis A; Dayal SP; Mohamed F; Cecil TD; Moran BJ
Ann Surg Oncol; 2021 Nov; 28(12):7809-7820. PubMed ID: 34041626
[TBL] [Abstract][Full Text] [Related]
40. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution.
Tabrizian P; Shrager B; Jibara G; Yang MJ; Romanoff A; Hiotis S; Sarpel U; Labow DM
J Gastrointest Surg; 2014 May; 18(5):1024-31. PubMed ID: 24577736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
